Business Context and Reporting Period
Company: Lineage Cell Therapeutics, Inc. (LCTX)
Filing Type: Form 8-K (Current Report)
Report Date: August 6, 2026
Reporting Period: Quarter ended June 30, 2026
This filing serves as a notification that the company issued a press release on August 6, 2026, announcing financial results for the second quarter of 2026. The detailed results are contained in Exhibit 99.1.
Key Financial Metrics
The provided text is a cover sheet for the Form 8-K and does not contain specific financial data. The following metrics are not present in this document:
- Revenue
- Profit/Loss
- Cash Flow
- Margins
- Debt and Liquidity
Note: Specific values for these metrics are not provided in the filing text; they are referenced as being available in the attached press release (Exhibit 99.1).
Material Changes
The filing text does not disclose specific material changes in financial condition or operations compared to prior periods. It only confirms the issuance of the Q2 2026 results announcement.
Guidance, Outlook, and Risks
Management Commentary: The filing states that the information is being furnished and is not being filed for purposes of Section 18 of the Exchange Act. Consequently, it is not to be incorporated by reference into any other filings unless expressly set forth by specific reference.
Guidance and Risks: No specific guidance, outlook, risk factors, or contingencies are detailed in this cover document.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for actual revenue, net loss, and cash position figures for the quarter ended June 30, 2026.
- Verify if the press release includes updated clinical trial timelines or regulatory milestones, as these are critical for a cell therapy company.
- Check for any forward-looking statements or guidance updates regarding the 2026 full-year outlook.
- Confirm the company's cash runway and any recent financing activities mentioned in the full press release.